Virtu Financial LLC Cuts Stake in Cardiff Oncology, Inc. $CRDF

by · The Cerbat Gem

Virtu Financial LLC lowered its stake in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF – Free Report) by 62.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,212 shares of the company’s stock after selling 31,969 shares during the period. Virtu Financial LLC’s holdings in Cardiff Oncology were worth $60,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. BNP Paribas Financial Markets purchased a new stake in shares of Cardiff Oncology during the fourth quarter worth about $25,000. Wells Fargo & Company MN increased its stake in shares of Cardiff Oncology by 38.1% during the fourth quarter. Wells Fargo & Company MN now owns 32,064 shares of the company’s stock worth $139,000 after purchasing an additional 8,851 shares in the last quarter. Barclays PLC increased its stake in shares of Cardiff Oncology by 17.9% during the fourth quarter. Barclays PLC now owns 62,596 shares of the company’s stock worth $272,000 after purchasing an additional 9,507 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Cardiff Oncology by 18.8% during the first quarter. Rhumbline Advisers now owns 63,142 shares of the company’s stock worth $198,000 after purchasing an additional 9,970 shares in the last quarter. Finally, Ledgewood Wealth Advisors LLC purchased a new stake in shares of Cardiff Oncology during the first quarter worth about $35,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Trading Down 0.4%

CRDF opened at $2.43 on Tuesday. The firm has a market capitalization of $161.67 million, a PE ratio of -2.79 and a beta of 1.54. Cardiff Oncology, Inc. has a twelve month low of $2.09 and a twelve month high of $5.64. The firm’s 50-day moving average price is $3.37 and its 200 day moving average price is $3.41.

Cardiff Oncology (NASDAQ:CRDF – Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Cardiff Oncology had a negative return on equity of 77.94% and a negative net margin of 9,344.14%. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.11 million. As a group, analysts predict that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Gary W. Pace bought 275,000 shares of Cardiff Oncology stock in a transaction on Wednesday, July 30th. The shares were bought at an average cost of $2.45 per share, with a total value of $673,750.00. Following the completion of the purchase, the director directly owned 1,330,676 shares of the company’s stock, valued at approximately $3,260,156.20. This trade represents a 26.05% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on CRDF shares. Jefferies Financial Group started coverage on shares of Cardiff Oncology in a research note on Tuesday, June 24th. They set a “hold” rating and a $3.50 target price for the company. William Blair restated an “outperform” rating on shares of Cardiff Oncology in a research report on Wednesday, June 18th. LADENBURG THALM/SH SH started coverage on shares of Cardiff Oncology in a research report on Tuesday, July 8th. They set a “buy” rating and a $19.00 price target on the stock. Finally, HC Wainwright lowered their price target on shares of Cardiff Oncology from $18.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Cardiff Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $10.10.

Check Out Our Latest Report on Cardiff Oncology

Cardiff Oncology Company Profile

(Free Report)

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Featured Stories